The Genetics of Medication Response
What Pharmacogenomic Testing Can (and Can’t) Tell Us
In recent years, pharmacogenomic (PGx) testing has emerged as a powerful tool, offering a DNA-based analysis of how a patient might metabolize psychiatric medications. Patients often ask, “Can I just take a test to tell me which antidepressant will work?” The answer is nuanced. PGx testing can tell us a lot about safety and tolerability, but it currently cannot tell us which drug will be effective.
PGx testing focuses primarily on genes in the Cytochrome P450 (CYP450) system, a family of liver enzymes responsible for metabolizing drugs. The most important of these for psychiatry are CYP2D6 and CYP2C19. Variations in these genes categorize patients into one of four metabolizer types:
Poor Metabolizers: Their liver processes the drug very slowly. A standard dose can lead to dangerously high blood levels, causing toxicity and severe side effects.
Intermediate Metabolizers: They process drugs slowly. They may require lower-than-standard doses to achieve a normal blood level.
Normal (Extensive) Metabolizers: They process drugs typically. Standard dosing is appropriate.
Ultra-rapid Metabolizers: Their liver processes the drug so quickly that it is eliminated before it can have an effect. They may require much higher-than-standard doses or will likely fail to respond to drugs reliant on that enzyme.
How does this help a clinician? If a patient has a history of failing multiple medications or experiencing bizarre, severe side effects from low doses, PGx testing can solve the mystery. It can show that the patient is a poor metabolizer of CYP2C19, explaining why they had severe toxicity on escitalopram (which is metabolized by that enzyme). The doctor can then choose a drug that is not metabolized by that pathway, such as sertraline or bupropion.
However, PGx testing has limitations. It does not predict efficacy. It cannot tell you if your depression will respond to a specific molecule. It also does not account for non-genetic factors like diet, other medications, kidney function, or liver health. Furthermore, while it can guide dosing and avoid toxicity, it is not yet a first-line requirement for all patients. It is most valuable for those who have already experienced treatment failures or unusual side effects.
Ultimately, PGx testing is a tool to reduce the “trial and error” in finding the right dose and avoiding dangerous side effects, but it is not a shortcut to finding the perfect drug on the first try.